Fulton Jessica, Popovetsky Gary, Jacoby Jeanne L, Heller Michael B, Reed James
Emergency Medicine Residency, St. Luke's Hospital, 801 Ostrum Street, Bethlehem, PA 18015, USA.
J Med Toxicol. 2006 Sep;2(3):93-6. doi: 10.1007/BF03161016.
Droperidol (DROP) is used in the emergency department (ED) for several indications, but its effect on psychomotor performance is unclear. The purpose of this study was to evaluate the effects of DROP, 2.5 mg intramuscular (IM), on driving performance.
This was a randomized, double-blinded, two-period, placebo-controlled crossover trial that utilized a standard driver-training program with computerized scoring. We solicited 20 paid volunteers who were pre-screened with a 12-lead EKG to evaluate QT length. For the first driving simulation, subjects were randomly assigned to receive either 2.5 mg of DROP IM or an equal volume of normal saline (NS). At least 72 hours later, the same subjects participated in a second driving simulation. For the second driving simulation, the assignment of DROP, 2.5 mg IM, or normal saline was reversed: (If a subject received DROP, 2.5 mg IM, in the first simulation, the subject received normal saline in the second simulation; conversely, if a subject received normal saline in the first simulation, the subject received DROP, 2.5 mg IM, in the second simulation). Thirty minutes later, participants drove the 20-minute simulation and received an average score based on the errors made in 4 categories: accelerating, braking, steering, and signaling. Post-testing, participants evaluated their degree of drowsiness and driving impairment using a visual analog scale and compared their perception of impairment to that caused by alcohol ingestion. Data were analyzed using analysis-of-variance, Pearson chi-square and Fischer's exact test with alpha set at p = 0.05.
Twenty subjects (11 males and 9 females) completed the protocol. The mean age was 30 years with a range of 20 to 46 years, and the mean weight was 80 kg. The mean driving experience was 12 years. Participants who received DROP felt significantly drowsier (38.6 mm +/- 9.0) than those receiving NS (13.2 mm +/- 9.0), the mean difference was 25.4 mm p = .009. Subjects receiving DROP were also more likely to feel that their driving would be impaired as rated on the VAS (DROP: 34.6 +/- 5.2; NS: 3.2 +/- 5.2; p = .0005), and DROP subjects reported impairment equivalent to 1-4 drinks more frequently than those receiving placebo (61% vs. 16.7%, p < .001). These subjective feelings of impairment were confirmed by their driving performance on the simulator. The mean driving score, using the driving simulator, was 68.8% with DROP vs. 73.6% with NS; p = .013.
Subjects receiving modest doses of IM DROP report increased perceptions of drowsiness, driving impairment, and intoxication; these perceptions are confirmed on objective testing.
氟哌利多(DROP)在急诊科用于多种适应证,但其对精神运动表现的影响尚不清楚。本研究的目的是评估2.5毫克肌内注射(IM)的DROP对驾驶性能的影响。
这是一项随机、双盲、两阶段、安慰剂对照的交叉试验,采用带有计算机评分的标准驾驶员培训项目。我们招募了20名有偿志愿者,他们预先接受了12导联心电图检查以评估QT间期。在第一次驾驶模拟中,受试者被随机分配接受2.5毫克的DROP肌内注射或等量的生理盐水(NS)。至少72小时后,同一受试者参加第二次驾驶模拟。在第二次驾驶模拟中,DROP 2.5毫克肌内注射或生理盐水的分配进行了反转:(如果一名受试者在第一次模拟中接受了2.5毫克的DROP肌内注射,那么该受试者在第二次模拟中接受生理盐水;相反,如果一名受试者在第一次模拟中接受了生理盐水,那么该受试者在第二次模拟中接受2.5毫克的DROP肌内注射)。30分钟后,参与者进行20分钟的模拟驾驶,并根据在加速、制动、转向和信号四个类别中所犯的错误获得平均分数。测试后,参与者使用视觉模拟量表评估他们的困倦程度和驾驶能力受损情况,并将他们对受损的感知与饮酒所导致的情况进行比较。使用方差分析、Pearson卡方检验和Fischer精确检验对数据进行分析,设定α为p = 0.05。
20名受试者(11名男性和9名女性)完成了方案。平均年龄为30岁,范围在20至46岁之间,平均体重为80千克。平均驾驶经验为12年。接受DROP的参与者比接受NS的参与者明显感觉更困倦(38.6毫米±9.0),平均差异为25.4毫米,p = 0.009。接受DROP的受试者在视觉模拟量表上也更有可能感觉他们的驾驶会受到损害(DROP:34.6±5.2;NS:3.2±5.2;p = 0.0005),并且接受DROP的受试者报告的受损程度相当于饮用1 - 4杯酒的频率高于接受安慰剂的受试者(61%对16.7%,p < 0.001)。这些主观的受损感觉通过他们在模拟器上的驾驶表现得到了证实。使用驾驶模拟器,接受DROP时的平均驾驶分数为68.8%,而接受NS时为73.6%;p = 0.013。
接受适量肌内注射DROP的受试者报告困倦感、驾驶能力受损和醉酒感增加;这些感觉在客观测试中得到了证实。